8.00 Registration and Coffee Registration and Coffee

8.40 Chairman's welcome Chairman's welcome

8.50 10 Minute Master Class – Networking In A Nutshell You all come to BioBusiness Network to do just that – to network. But are you doing this as effectively as you can? In this ten minute session, you will learn cutting-edge techniques to improve how you network and truly make the most out of your two days at BioBusiness Network 2010.

9.00 Roche-Galapagos COPD Alliance – €400 Million Risk Sharing In Target Discovery To Product Onno Van De Stolpe, CEO, Galapagos Louk Pechtold, Director Business Development, Roche Unique target discovery platform of Galapagos basis of alliance Alliance covers both small molecules and antibody targets Galapagos runs programs in small molecules through to clinic Risk based alliance: success based milestones and royalties for Galapagos, option to license for Roche Prime example on how biotech–pharma deals are changing from contract research and in-licensing to risk sharing in combination with opt-in Onno Van De Stolpe CEO, Galapagos Louk Pechtold Director Business Development, Roche

9.30 Panel Discussion: Big Pharma Outlook To 2015 - Key Strategies To Achieve Growth Gary Buell, Head of Search & Evaluation, Early Stage Licensing, Merck Serono Marianne De Backer, VP Licensing and Business Development, Johnson & Johnson Assessing the M&A landscape: how is the pharma world changing Analysing Big Pharma's current business model and the mergers, acquisitions and divestments that have shaped the industry What are the blockbuster drugs for the next five years? Is business development a major contributor to future growth in a tough market? Opportunities and prospects in 2011 Gary Buell Head of Search & Evaluation, Early Stage Licensing, Merck Serono Marianne De Backer VP Licensing and Business Development, Johnson & Johnson

10.00 Speed Networking Introducing the fastest and most effective way to meet the entire delegate audience! In just twenty minutes you will have the opportunity to meet and exchange business cards with everyone in the room!

10.30 Morning Coffee Morning Coffee

11.00 Living Science, Transformign Lived Christoph Huels, Vice President Early Stage Licensing , Merck Serono An overview of Merck Serono company activities Assessing the company's approach to innovation and collaboration models Key interests for collaboration with external parties Christoph Huels Vice President Early Stage Licensing , Merck Serono

11.30 Biotech CEO Panel: Elan Drug Technologies-Acorda Therapeutics Ampyra Licensing and Development Partnership – The Noleen Kenny, VP Comercial Management, Elan Drg Technologies Early work in 1990’s in Elan on molecule Acorda’s involvement - history of alliances between Elan and Acorda from 1997 to present The challenge of 4-AP and the formulation and process approach taken by Elan Drug Technologies The MXDAS™ technology, the clinical programme undertaken by Acorda and the launch in 2010 of Ampyra™ (dalfampridine) Attributes of a successful business partnership and lessons learned Noleen Kenny VP Comercial Management, Elan Drg Technologies

12.00 Biotech CEO Panel: Key Trends And The Biotech Vision For 2011 Roland Kozlowski, CEO, Lectus Therapeutics Alex Wu, CEO, Crown Biosciences Inc Rainer Lichtenberger, CEO, CEVEC Francois Curtin, CEO, Geneuro Will biotechs continue to play the role of chief innovator? The increase in virtualisation: what do biotechs need to do to stay ahead? How can biotech companies maintain a competitive edge in a challenging market? Exploring alternative funding strategies to secure deals and progress projects Roland Kozlowski CEO, Lectus Therapeutics Alex Wu CEO, Crown Biosciences Inc Rainer Lichtenberger CEO, CEVEC Francois Curtin CEO, Geneuro

12.30 The Perfect Pitch: Biotech Investment Challenge In this innovative session, 6 Biotechs all focused on different therapeutic areas, will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts. Each Biotech will give a 10 minute company presentation highlighting their current projects. Then our panellists, consisting of big Pharma, VCs and Investment Banks will give their feedback on the strengths of the pitches just heard- highlighting the portions of the presentations that piqued their interest. This will not only give the presenting companies the platform to attract new partners, but will also give the presenting companies, and audience alike, insight into what sparks the interest of potential partners and investors. This session is a must attend for Pharma, Biotechs, and the investment community. The panellists will then have a chance to confer and choose “the perfect pitch” which will be presented a BioBusiness Network Award Contact Michaela Menezes on michaela.menezes@wbr.co.uk to find out more and join this exciting challenge. • Biotech #1 presentation (Oncology) • Biotech #2 presentation (CNS & Psychiatry) • Biotech #3 presentation (Cardiovascular) • Biotech #4 presentation (Diabetes/Metabolic) • Biotech #5 presentation (Infectious Disease)• Biotech #6 presentation (Auto-Immune (HIV))

13.30 Networking Lunch No session description available.

14.30 Mastering The Art Of A Winning Pitch: Achieve A Competitive Edge and Secure Funding What are pharma companies looking for from your pitch? What constitutes a perfect pitch – from content to delivery? Delivering a first class pitch – dos and don’ts Improving your communication style to align with Big Pharma Positioning your product heads and shoulders above the competition

15.00 Early Partnering Case Study: GSK / Astex – Building A Unique Strategic Drug Discovery Alliance Jeremy Carmichael, Head fo Business Development, Astex, and leading representative, GSK, Indentifying the drivers that led to the early-stage deal An overview of the GSK model and the basis of the GSK / Astex collaboration Outlining the alternatives to an option-based deal Key steps to progressing the partnership within predefined parameters Jeremy Carmichael Head fo Business Development, Astex, and leading representative, GSK,

15.30 Afternoon Tea Afternoon Tea

16.30 Improving Corporate Social Responsibility Via Public- Improving Corporate Social Responsibility Via Public- Patrick Nef, Chief Business Officer, MMV What socially responsible licensing means How to ensure the dissemination of safe, efficacious and affordable treatments fordeveloping countries The product-development public-private partnership model for a global health impact The MMV partnering and funding strategies to defeat malaria: 10 years of success/impact Patrick Nef Chief Business Officer, MMV

17.00 Round Table Discussions No session description available.

18.00 Drinks Reception Drinks Reception

19:00 Networking Dinner Networking Dinner